The inability of antiretroviral therapy (ART) to clear HIV infection and the observation that a sterilizing cure and/or stable remission can be achieved by a subset of ART-treated persons has galvanized interest to advance clinical strategies towards a cure and/or stable remission. Including scientists from 12 institutions and 9 industry partners, the BEAT-HIV Delaney Collaboratory will seek to develop and test innovative combined immunotherapy strategies to permanently suppress and/or eradicate HIV in the absence of ART. Dr. Robert Siliciano is a co-PI of the collaborative.